Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503444 | 0.98 | CA14 (0.53) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL28584989 | 0.96 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL27252832 | 0.90 | CA14 (0.55) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL1031568 | 0.90 | CA14 (0.47) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL10418789 | 0.90 | CA14 (0.59) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL16471754 | 0.88 | CA14 (0.46) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL4696802 | 0.88 | CA14 (0.46) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL13661113 | 0.88 | CA14 (0.50) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL896291 | 0.88 | CA14 (0.45) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL23857521 | 0.87 | CA14 (0.45) | CA14SSTR4HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430001-B1 | METHODS FOR THE PREPARATION OF AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | JUVARIS BIOTHERAPEUTICS INC (US) | 2013-12-11 | — | — | EP | disclosed |
| EP-2430001-A1 | METHODS FOR THE PREPARATION OF AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | Juvaris Biotherapeutics, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8044215-B2 | Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8044215-B2 | Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2010126978-A1 | METHODS FOR THE PREPARATION OF AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126978-A1 | METHODS FOR THE PREPARATION OF AMPHIPHILIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280258-A1 | METHODS FOR THE PREPARATION OF AMPHILLIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280258-A1 | METHODS FOR THE PREPARATION OF AMPHILLIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | JUVARIS BIOTHERAPEUTICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280258-A1 | METHODS FOR THE PREPARATION OF AMPHILLIC NITROGEN CONTAINING IMIDAZOLINIUM DERIVATIVE COMPOUNDS | NDC1, NUP205, NUP188 | CA14 3792/4885SSTR4 2855/4885HDAC6 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.